Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Schizophrenia

Free Subscription Articles published in Mol Psychiatry Retrieve available abstracts of 242 articles: HTML format

Single Articles

September 2026
1. WU Y, Gao Y, Li M, Zhang CY, et al
   Developmental and cellular vulnerabilities underlie genetic architecture of schizophrenia.
   Mol Psychiatry. 2026 Sep 3. doi: 10.1038/s41380-026-03862.
   PubMed     Abstract available
   
   
   
2. WANG X, Luo L, Chang S, Yang L, et al
   Cell-type-specific genetic architecture reveals neuronal and immune contributions to neuropsychiatric disorders.
   Mol Psychiatry. 2026;31:5145-5161.
   PubMed     Abstract available
   
   
   
3. KIRSCHNER M, Hodzic-Santor B, Kennedy L, Hansen JY, et al
   Multiscale characterization of cortical signatures in positive and negative schizotypy: a worldwide ENIGMA study.
   Mol Psychiatry. 2026;31:4846-4860.
   PubMed     Abstract available
   
   
   August 2026
4. LI X, Chen M, Tang E, Fu J, et al
   HD-tDCS modulation of the DLPFC-HPC-EC pathway to enhance working memory in schizophrenia: a TMS-EEG Study.
   Mol Psychiatry. 2026 Aug 21. doi: 10.1038/s41380-026-03835.
   PubMed     Abstract available
   
   
   
5. PENZEL N, Cho KIK, Seitz-Holland J, Ruef A, et al
   Disentangling white matter correlates of symptom severity and general impairment in early psychosis.
   Mol Psychiatry. 2026 Aug 20. doi: 10.1038/s41380-026-03832.
   PubMed     Abstract available
   
   
   
6. ZHANG C, Dong Y, Li T, Han Y, et al
   Metabolic biomarkers of treatment-resistant schizophrenia and cognitive correlates: insights from a machine learning.
   Mol Psychiatry. 2026 Aug 19. doi: 10.1038/s41380-026-03827.
   PubMed     Abstract available
   
   
   
7. IM J, Mai M, Mimaki K, Tang L, et al
   The NLRP3 inflammasome: pathophysiology and therapeutic implications for schizophrenia and neuropsychiatric disorders.
   Mol Psychiatry. 2026 Aug 12. doi: 10.1038/s41380-026-03821.
   PubMed     Abstract available
   
   
   
8. DIENEL SJ, Vespoli JC, Lewis DA, Fish KN, et al
   Molecular alterations in chondrolectin-containing somatostatin neurons in schizophrenia differ based on circuit context.
   Mol Psychiatry. 2026 Aug 10. doi: 10.1038/s41380-026-03763.
   PubMed     Abstract available
   
   
   
9. CONNOLLY JG, Blyth SH, Yildiz G, Rogers BP, et al
   Accelerated DMN-targeted cTBS improves processing speed deficits in schizophrenia.
   Mol Psychiatry. 2026 Aug 5. doi: 10.1038/s41380-026-03798.
   PubMed     Abstract available
   
   
   
10. DAS U, Crowley JJ, Karlsson R, Lu Y, et al
    The association of schizophrenia polygenic scores with continuously-hospitalized, treatment-resistant schizophrenia.
    Mol Psychiatry. 2026 Aug 4. doi: 10.1038/s41380-026-03806.
    PubMed     Abstract available
    
    
    
11. JEN Y, Yu SL, Hsiao PC, Kuo PH, et al
    Correction: Identification of hub genes involved in early-onset schizophrenia: from genetic susceptibility to predicted regulated gene expression.
    Mol Psychiatry. 2026 Aug 3. doi: 10.1038/s41380-026-03781.
    PubMed    
    
    
    
12. KUBOTA M, Kurose S, Tagai K, Momota Y, et al
    High prevalence of tau pathologies in late-onset psychosis: A PET study.
    Mol Psychiatry. 2026 Aug 3. doi: 10.1038/s41380-026-03749.
    PubMed     Abstract available
    
    
    July 2026
13. OKADA N, Morita K, Tonsho S, Kiyota M, et al
    The role of the globus pallidus subregions in the schizophrenia spectrum continuum.
    Mol Psychiatry. 2026 Jul 10. doi: 10.1038/s41380-026-03729.
    PubMed     Abstract available
    
    
    
14. EYLES D, Du Z, Cui X, Kesby J, et al
    "Increasing dopamine synthesis capacity in the dorsal striatum and tonic acetylcholine: implications for the new muscarinic agents in the treatment of schizophrenia".
    Mol Psychiatry. 2026 Jul 9. doi: 10.1038/s41380-026-03758.
    PubMed    
    
    
    
15. LEVITT JJ, Zhang F, Vangel M, Nestor PG, et al
    Diagnostic and sex effects on frontostriatal brain wiring structural organization in early psychosis affective subjects compared to healthy controls.
    Mol Psychiatry. 2026 Jul 4. doi: 10.1038/s41380-026-03719.
    PubMed     Abstract available
    
    
    
16. ROBINSON N, Ploner A, Ohlsson H, Lichtenstein P, et al
    Effects of family genetic risk scores and environmental factors on risk of schizophrenia and bipolar disorder.
    Mol Psychiatry. 2026 Jul 3. doi: 10.1038/s41380-026-03715.
    PubMed     Abstract available
    
    
    
17. JEN Y, Yu SL, Hsiao PC, Kuo PH, et al
    Identification of hub genes involved in early-onset schizophrenia: from genetic susceptibility to predicted regulated gene expression.
    Mol Psychiatry. 2026 Jul 3. doi: 10.1038/s41380-026-03731.
    PubMed     Abstract available
    
    
    
18. ZHAO G, Sun Y, Lu Z, Kang Z, et al
    Identifying genetic contributions of 6q21 loci and PPAR pathway to antipsychotic-induced metabolic syndrome: a Sex-Stratified Multi-Omics study.
    Mol Psychiatry. 2026;31:4154-4163.
    PubMed     Abstract available
    
    
    
19. FENG Y, Jia N, Huang P, Hu S, et al
    Cross-ancestry genetic architecture reveals shared biological pathways of major psychiatric disorders.
    Mol Psychiatry. 2026;31:4083-4095.
    PubMed     Abstract available
    
    
    
20. GIACOMEL A, Powell TR, Duarte RRR, Nordio G, et al
    Transcriptome-informed brain cartography of polygenic risk and association with brain structure in major psychiatric disorders.
    Mol Psychiatry. 2026;31:3965-3977.
    PubMed     Abstract available
    
    
    
21. GUO Z, Zhao W, Li J, Zhang H, et al
    Exploring the impact of cognitive profiles on the response to magnetic seizure therapy and electroconvulsive therapy.
    Mol Psychiatry. 2026;31:3653-3661.
    PubMed     Abstract available
    
    
    
22. CHEN Y, Cheng L, Wang Q, Liu Q, et al
    Shared genetic architecture of schizophrenia and Alzheimer's disease and related dementias implicates 16p11.2 and lifespan brain vulnerability.
    Mol Psychiatry. 2026 Jul 1. doi: 10.1038/s41380-026-03735.
    PubMed     Abstract available
    
    
    June 2026
23. ROALF DR, Moore TM, Stifelman J, Pecsok MK, et al
    Cannabis use and glutamate across the psychosis spectrum: in vivo evidence from 7T proton magnetic resonance spectroscopy.
    Mol Psychiatry. 2026 Jun 27. doi: 10.1038/s41380-026-03705.
    PubMed     Abstract available
    
    
    
24. CHOPRA S, Worhunsky PD, Naganawa M, Zhang XH, et al
    Widespread synaptic density loss in schizophrenia follows molecular and network architecture.
    Mol Psychiatry. 2026 Jun 25. doi: 10.1038/s41380-026-03717.
    PubMed     Abstract available
    
    
    
25. JELOVAC A, Braithwaite R
    Re-evaluating response rates, time to reorientation and inadequate seizure duration in magnetic seizure therapy for schizophrenia and major depression.
    Mol Psychiatry. 2026 Jun 22. doi: 10.1038/s41380-026-03699.
    PubMed    
    
    
    
26. FRENCH H, Yao S, Bast L, Roig Adam A, et al
    Developmentally dynamic, non-convergent transcriptomic profiles in CNV models for schizophrenia risk.
    Mol Psychiatry. 2026 Jun 18. doi: 10.1038/s41380-026-03679.
    PubMed     Abstract available
    
    
    
27. YU T, Lu Z, Huang B, Sun Y, et al
    Distinct contributions of schizophrenia and neurotransmitter pathway genetic liability to neurocognition and antipsychotic efficacy in drug-naive first-episode schizophrenia.
    Mol Psychiatry. 2026 Jun 15. doi: 10.1038/s41380-026-03684.
    PubMed     Abstract available
    
    
    
28. CRAMER TML, Hannan SB, Petre L, Bear MF, et al
    Schizophrenia-associated glycoprotein Adamtsl3 regulates perineuronal net formation, maintenance, and adult cortical plasticity.
    Mol Psychiatry. 2026 Jun 11. doi: 10.1038/s41380-026-03672.
    PubMed     Abstract available
    
    
    
29. LUTHER L, Cooper JA, Treadway MT, Knippenberg AR, et al
    Computational phenotypes underlying effort-based decision-making and negative symptoms in a transdiagnostic severe mental illness sample.
    Mol Psychiatry. 2026;31:3435-3445.
    PubMed     Abstract available
    
    
    
30. XUE H, Lei M, Zhao Q, Zhang Z, et al
    Powering the mind: deciphering the shared genetic architecture between mitochondrial DNA copy number and major psychiatric disorders.
    Mol Psychiatry. 2026;31:3127-3138.
    PubMed     Abstract available
    
    
    May 2026
31. CHENG P, Liu Z, Li X, Wang F, et al
    A hierarchical multi-scale framework for schizophrenia: integrating symptom networks, functional circuits, and molecular pathways.
    Mol Psychiatry. 2026 May 30. doi: 10.1038/s41380-026-03668.
    PubMed     Abstract available
    
    
    
32. BARENDSE MEA, Poortman SR, Ching CRK, Cahn W, et al
    White matter microstructure in relatives of people with schizophrenia or bipolar disorder: an ENIGMA meta-analysis.
    Mol Psychiatry. 2026 May 21. doi: 10.1038/s41380-026-03628.
    PubMed     Abstract available
    
    
    
33. OWEN MJ, O'Donovan MC
    Rethinking schizophrenia: insights from genomics and implications for research.
    Mol Psychiatry. 2026 May 21. doi: 10.1038/s41380-026-03654.
    PubMed     Abstract available
    
    
    
34. NERLAND S, Barth C, Jorgensen KN, Wortinger LA, et al
    Cerebral cortical alterations in adolescent early-onset psychosis: a surface-based morphometry mega-analysis.
    Mol Psychiatry. 2026 May 19. doi: 10.1038/s41380-026-03641.
    PubMed     Abstract available
    
    
    
35. JUNG S, Caballero M, Kepinska A, Smout S, et al
    Genetic architecture of postpartum psychosis: from common to rare genetic variation.
    Mol Psychiatry. 2026 May 14. doi: 10.1038/s41380-026-03637.
    PubMed     Abstract available
    
    
    
36. KIELHOLD ML, Jacobs DS, Torrado Pacheco A, Lefner MJ, et al
    Grin2a knockout in adolescent dopamine neurons disrupts prediction error signaling and produces a phenotype relevant to schizophrenia.
    Mol Psychiatry. 2026 May 13. doi: 10.1038/s41380-026-03632.
    PubMed     Abstract available
    
    
    
37. WANG H, Bundo M, Nakachi Y, Kanai A, et al
    Maternal fasting during early gestation induces epigenetic alterations and schizophrenia-related phenotypes.
    Mol Psychiatry. 2026 May 13. doi: 10.1038/s41380-026-03629.
    PubMed     Abstract available
    
    
    
38. LOU W, Dang X, Luo XJ
    Integrating cell-type-specific gene expression and genome-wide associations identifies risk genes for schizophrenia.
    Mol Psychiatry. 2026 May 9. doi: 10.1038/s41380-026-03652.
    PubMed     Abstract available
    
    
    
39. CAO L, Maleki Balajoo S, Gao Y, Li H, et al
    Common alterations of whole and subregion-specific amygdala intrinsic functional connectivity across psychiatric disorders: a meta-analysis.
    Mol Psychiatry. 2026;31:2916-2926.
    PubMed     Abstract available
    
    
    April 2026
40. REICHENBERG A, Kahn RS
    Cognitive impairment preceding the onset of the first psychosis episode in schizophrenia.
    Mol Psychiatry. 2026 Apr 28. doi: 10.1038/s41380-026-03625.
    PubMed     Abstract available
    
    
    
41. WANG L, Xu K, Liao Y, Luo Y, et al
    Astrocytic connexin 43 hemichannel dysregulation drives prefrontal circuit dysfunction and schizophrenia-like behaviors.
    Mol Psychiatry. 2026 Apr 27. doi: 10.1038/s41380-026-03621.
    PubMed     Abstract available
    
    
    
42. NUSSBAUMER M, Guest PC, Schiltz K, Dudeck L, et al
    Multimodal microglial and kynurenine pathway alterations across the affective-psychosis spectrum: a systematic review of patterns, heterogeneity, and dimensional implications.
    Mol Psychiatry. 2026 Apr 21. doi: 10.1038/s41380-026-03614.
    PubMed     Abstract available
    
    
    
43. CUI L, Kurganov E, Hawes D, Hornauer P, et al
    Loss of schizophrenia risk gene XPO7 disrupts neuronal excitability and network regularity via altered Na(+) channel dynamics in human neurons.
    Mol Psychiatry. 2026 Apr 15. doi: 10.1038/s41380-026-03587.
    PubMed     Abstract available
    
    
    
44. CHENG M, Yin Y, Engchuan W, Heung T, et al
    Genome-wide tandem repeat expansions modify schizophrenia risk in the presence of a 22q11.2 deletion.
    Mol Psychiatry. 2026 Apr 15. doi: 10.1038/s41380-026-03574.
    PubMed     Abstract available
    
    
    
45. MCKENNA F, Vinke LN, Williams M, Gaw M, et al
    Postpartum psychosis is associated with elevated neuromelanin-MRI signal in the midbrain.
    Mol Psychiatry. 2026 Apr 15. doi: 10.1038/s41380-026-03476.
    PubMed     Abstract available
    
    
    
46. FENNER E, Holmans P, O'Donovan MC, Owen MJ, et al
    Analysis of rare coding variants in schizophrenia-associated genes and generalised cognition in the UK Biobank.
    Mol Psychiatry. 2026 Apr 10. doi: 10.1038/s41380-026-03601.
    PubMed     Abstract available
    
    
    
47. YANG X, Agartz I, Andreassen O, Bachman P, et al
    Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis.
    Mol Psychiatry. 2026 Apr 4. doi: 10.1038/s41380-026-03586.
    PubMed     Abstract available
    
    
    
48. DAI SS, Dang X, Gong D, Li D, et al
    Molecular regulatory mechanisms of schizophrenia-associated functional non-coding variants.
    Mol Psychiatry. 2026 Apr 2. doi: 10.1038/s41380-026-03566.
    PubMed     Abstract available
    
    
    
49. SEUFFERT S, Mulfarth RR, Teutenberg L, Thomas-Odenthal F, et al
    Linking speech patterns to brain structure in affective and psychotic disorders: an integrative natural language processing approach.
    Mol Psychiatry. 2026;31:2057-2068.
    PubMed     Abstract available
    
    
    
50. LI Q, Liu J, Pearlson GD, Chen J, et al
    Spatiotemporal complexity in the psychotic brain.
    Mol Psychiatry. 2026;31:2014-2028.
    PubMed     Abstract available
    
    
    
51. TANAKA R, Liao J, Liu Y, Zhu W, et al
    Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia.
    Mol Psychiatry. 2026 Apr 1. doi: 10.1038/s41380-026-03567.
    PubMed     Abstract available
    
    
    March 2026
52. ETYEMEZ S, Sivananthan R, Faria AV, Iasevoli F, et al
    Brain structural abnormalities in treatment-resistant schizophrenia.
    Mol Psychiatry. 2026 Mar 28. doi: 10.1038/s41380-026-03558.
    PubMed     Abstract available
    
    
    
53. ZHANG S, Chen Y, Zhang L, Yang X, et al
    Global lifetime prevalence of schizophrenia: A systematic review and meta-analysis.
    Mol Psychiatry. 2026 Mar 23. doi: 10.1038/s41380-026-03533.
    PubMed     Abstract available
    
    
    
54. DAMIANI S, Stefanelli R, Fortea L, D'Imperio A, et al
    Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials.
    Mol Psychiatry. 2026 Mar 23. doi: 10.1038/s41380-026-03543.
    PubMed     Abstract available
    
    
    
55. OLIVER LD, Yu JC, Hawco C, Calarco N, et al
    Multivariate relationships between social cognitive performance and functional connectivity during task and rest across schizophrenia spectrum disorders and healthy controls.
    Mol Psychiatry. 2026 Mar 12. doi: 10.1038/s41380-026-03504.
    PubMed     Abstract available
    
    
    
56. LAABOUB N, Vandenberghe F, Ansermot N, Piras M, et al
    Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analyses.
    Mol Psychiatry. 2026;31:1420-1430.
    PubMed     Abstract available
    
    
    February 2026
57. LI X, Zeng J, Liu N, Tang B, et al
    Functional brain abnormalities of cognitive impairments in schizophrenia indicating higher integration of working memory than other domains.
    Mol Psychiatry. 2026 Feb 27. doi: 10.1038/s41380-026-03518.
    PubMed     Abstract available
    
    
    
58. KINJO M, Tamura S, Sugiyama S, van Weert E, et al
    A systematic review and meta-analysis of the auditory steady-state response in schizophrenia, bipolar disorder, and autism spectrum disorder.
    Mol Psychiatry. 2026 Feb 3. doi: 10.1038/s41380-026-03452.
    PubMed     Abstract available
    
    
    
59. DE SIMONE G, De Prisco M, Oliva V, Vellucci L, et al
    Molecular and topographic mapping of antipsychotic effects: a meta-analysis of postsynaptic density proteins in animal models with translational implications.
    Mol Psychiatry. 2026;31:1142-1155.
    PubMed     Abstract available
    
    
    January 2026
60. WATSON CJ, Zvrskovec J, Merola GP, Gilchrist L, et al
    Splitting schizophrenia: divergent cognitive and educational outcomes revealed by genomic structural equation modelling.
    Mol Psychiatry. 2026 Jan 31. doi: 10.1038/s41380-026-03444.
    PubMed     Abstract available
    
    
    
61. LLORCA-BOFI V, Parellada E, Moren C, Sellgren CM, et al
    Neuroinflammation: an unfortunate term to describe schizophrenia.
    Mol Psychiatry. 2026 Jan 31. doi: 10.1038/s41380-026-03450.
    PubMed     Abstract available
    
    
    
62. MEMETOGLU O, Goyal MS, Chouinard VA, Du F, et al
    Aerobic glycolysis in Schizophrenia: Developmental rescue or energetic breakdown?
    Mol Psychiatry. 2026 Jan 31. doi: 10.1038/s41380-026-03460.
    PubMed     Abstract available
    
    
    
63. UCHIYAMA S, Saito T, Liu X, Ishikawa Y, et al
    Associations between mosaic loss and schizophrenia or bipolar disorder of young age.
    Mol Psychiatry. 2026 Jan 15. doi: 10.1038/s41380-025-03397.
    PubMed     Abstract available
    
    
    
64. LEMKE JR, Eoli A, Krey I, Popp B, et al
    Correction: GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy.
    Mol Psychiatry. 2026 Jan 7. doi: 10.1038/s41380-025-03442.
    PubMed    
    
    
    December 2025
65. WANG L, Zhang J, Geng L, Chen B, et al
    Associative memory neurons are recruited in PFC-centered circuits to encode schizophrenia-like behavior by dopaminergic receptor-II.
    Mol Psychiatry. 2025 Dec 15. doi: 10.1038/s41380-025-03388.
    PubMed     Abstract available
    
    
    
66. DANG X, Gong D, Dai SS, Teng Z, et al
    Genetic and functional insights into long noncoding RNAs in schizophrenia.
    Mol Psychiatry. 2025 Dec 14. doi: 10.1038/s41380-025-03421.
    PubMed     Abstract available
    
    
    
67. CHU RS, Fung VS, Lei JH, Wong GH, et al
    Rate and predictors of remission and recovery in first-episode psychosis: A 12-year follow-up of randomized-controlled trial on early intervention.
    Mol Psychiatry. 2025 Dec 12. doi: 10.1038/s41380-025-03409.
    PubMed     Abstract available
    
    
    
68. HARTMANN SM, Pizarro Garcia P, Heider J, Vogel S, et al
    A co-culture model of dopaminergic and glutamatergic neurons derived from patients with idiopathic schizophrenia reveals a hypodopaminergic phenotype.
    Mol Psychiatry. 2025 Dec 12. doi: 10.1038/s41380-025-03384.
    PubMed     Abstract available
    
    
    
69. LAMSMA J, Raine A, Kia SM, Cahn W, et al
    Structural brain abnormalities and aggression in schizophrenia: mega-analysis of data from 2095 patients and 2861 healthy controls via the ENIGMA consortium.
    Mol Psychiatry. 2025 Dec 3. doi: 10.1038/s41380-025-03365.
    PubMed     Abstract available
    
    
    November 2025
70. POWELL SK, Liao W, Ghorbani S, Rigat R, et al
    3D genetic architecture of schizophrenia risk across three neuronal subtypes.
    Mol Psychiatry. 2025 Nov 28. doi: 10.1038/s41380-025-03352.
    PubMed     Abstract available
    
    
    
71. ZHANG T, Xu L, Wei Y, Cui H, et al
    Cognitive trajectories of psychosis risk: temporal patterns and association with progression.
    Mol Psychiatry. 2025 Nov 23. doi: 10.1038/s41380-025-03371.
    PubMed     Abstract available
    
    
    
72. YE L, Ni C, Chen R, Che S, et al
    Mendelian randomization facilitates identification of schizophrenia risk enhancer RNAs.
    Mol Psychiatry. 2025 Nov 23. doi: 10.1038/s41380-025-03358.
    PubMed     Abstract available
    
    
    
73. MARTIN ECHAVE M, Schnack HG, Diaz-Caneja CM, Pina-Camacho L, et al
    Individualized cortical thickness asymmetry in autism spectrum disorder and schizophrenia.
    Mol Psychiatry. 2025 Nov 23. doi: 10.1038/s41380-025-03359.
    PubMed     Abstract available
    
    
    
74. DEAKIN B, Liddle E, Rathnaiah M, Gregory CC, et al
    Investigating the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences.
    Mol Psychiatry. 2025 Nov 19. doi: 10.1038/s41380-025-03337.
    PubMed     Abstract available
    
    
    
75. VELEZ-PEREZ E, Demirlek C, Zeng V, Silverstein S, et al
    Retinal cytoarchitectural alterations across the psychosis spectrum and their correlates with cognition: a UK biobank nested case-control study.
    Mol Psychiatry. 2025 Nov 15. doi: 10.1038/s41380-025-03343.
    PubMed     Abstract available
    
    
    
76. CRESPI BJ
    Evaluating evidence for convergence between autism and schizophrenia.
    Mol Psychiatry. 2025 Nov 1. doi: 10.1038/s41380-025-03334.
    PubMed    
    
    
    October 2025
77. BATALLA A, Somers M, Meer PV
    Psychedelics, psychosis, and the elusive notion of safety.
    Mol Psychiatry. 2025 Oct 24. doi: 10.1038/s41380-025-03315.
    PubMed    
    
    
    
78. LIU S, Agartz I, Allen P, Amminger GP, et al
    Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study.
    Mol Psychiatry. 2025 Oct 22. doi: 10.1038/s41380-025-03304.
    PubMed     Abstract available
    
    
    
79. HU Y, Wang Z, Fang J, Zhang S, et al
    Selective magnetic stimulation downregulates the GABA(A) receptor epsilon subunit in the left prelimbic cortex to alleviate schizophrenia-like behaviors in mice.
    Mol Psychiatry. 2025 Oct 14. doi: 10.1038/s41380-025-03267.
    PubMed     Abstract available
    
    
    
80. LEMKE JR, Eoli A, Krey I, Popp B, et al
    GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy.
    Mol Psychiatry. 2025 Oct 14. doi: 10.1038/s41380-025-03279.
    PubMed     Abstract available
    
    
    
81. WALTHER S, Maderthaner L, Chapellier V, von Kanel S, et al
    Gesture deficits in psychosis and the combination of group psychotherapy and transcranial magnetic stimulation: A randomized clinical trial.
    Mol Psychiatry. 2025 Oct 8. doi: 10.1038/s41380-025-03303.
    PubMed     Abstract available
    
    
    
82. MARTINEZ-SADURNI L, Barrera-Conde M, Robledo P, Veza-Estevez E, et al
    Differential effect of cannabis use and antipsychotic medication on extracellular free-water in the brain of individuals with early psychosis and controls.
    Mol Psychiatry. 2025 Oct 7. doi: 10.1038/s41380-025-03287.
    PubMed     Abstract available
    
    
    
83. CARR R, Cannon A, Finelli V, Bukala B, et al
    Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis.
    Mol Psychiatry. 2025 Oct 3. doi: 10.1038/s41380-025-03255.
    PubMed     Abstract available
    
    
    
84. OHTANI H, Ichikawa R, Mori K, Kato T, et al
    Single-molecule DNA analysis implicates brain mitochondria pathology in bipolar disorder.
    Mol Psychiatry. 2025;30:4764-4775.
    PubMed     Abstract available
    
    
    
85. DARDANI C, Robinson JW, Jones HJ, Rai D, et al
    Immunological drivers and potential novel drug targets for major psychiatric, neurodevelopmental, and neurodegenerative conditions.
    Mol Psychiatry. 2025;30:4487-4496.
    PubMed     Abstract available
    
    
    September 2025
86. LU ZA, Ploner A, Birgegard A, Landen M, et al
    Leveraging transdiagnostic genetic liability to psychiatric disorders to dissect clinical outcomes of anorexia nervosa.
    Mol Psychiatry. 2025 Sep 23. doi: 10.1038/s41380-025-03264.
    PubMed     Abstract available
    
    
    
87. SINANAJ L, Pallis K, Dehkordi AF, Huguelet P, et al
    Mapping symptom-general and symptom-specific targets for transcranial magnetic stimulation in schizophrenia: an electric-field modeling meta-analysis.
    Mol Psychiatry. 2025 Sep 22. doi: 10.1038/s41380-025-03238.
    PubMed     Abstract available
    
    
    
88. SU X, Zhang H, Hong Y, Yang Q, et al
    Mutations of schizophrenia risk gene SETD1A dysregulate synaptic function in human neurons.
    Mol Psychiatry. 2025 Sep 17. doi: 10.1038/s41380-025-03246.
    PubMed     Abstract available
    
    
    
89. BOJESEN KB, Lemvigh CK, Sigvard AK, Vestergaard MB, et al
    Cerebral glutamate levels over two years in initially antipsychotic-naive first-episode patients with psychosis are related to clinical symptoms and cognition.
    Mol Psychiatry. 2025 Sep 15. doi: 10.1038/s41380-025-03234.
    PubMed     Abstract available
    
    
    
90. BOJESEN KB, Ambrosen KS, Sigvard AK, Nielsen MO, et al
    Interrelations between dopaminergic-, gabaergic- and glutamatergic neurotransmitters in antipsychotic-naive psychosis patients and the association to initial treatment response.
    Mol Psychiatry. 2025 Sep 12. doi: 10.1038/s41380-025-03229.
    PubMed     Abstract available
    
    
    
91. LUKOW PB, Schubert JJ, Severino M, Knight SR, et al
    GABA(A) receptor availability in clinical high-risk and first-episode psychosis: a [(11)C]Ro15-4513 positron emission tomography study.
    Mol Psychiatry. 2025 Sep 6. doi: 10.1038/s41380-025-03204.
    PubMed     Abstract available
    
    
    
92. VANO LJ, McCutcheon RA, Sedlacik J, Rutigliano G, et al
    The role of low subcortical iron, white matter myelin, and oligodendrocytes in schizophrenia: a quantitative susceptibility mapping and diffusion tensor imaging study.
    Mol Psychiatry. 2025 Sep 5. doi: 10.1038/s41380-025-03195.
    PubMed     Abstract available
    
    
    
93. AHIRWAR LK, Blackburn SL, McBride DW, T PK, et al
    Reviewing vascular influences on neuronal migration, cortical development, and neurodevelopmental disorders: focus on autism, ADHD and schizophrenia.
    Mol Psychiatry. 2025 Sep 2. doi: 10.1038/s41380-025-03200.
    PubMed     Abstract available
    
    
    
94. LU Z, Guo J, Sun J, Sun Y, et al
    The event-related potential components across psychiatric disorders: a systematic review and network meta-analysis.
    Mol Psychiatry. 2025;30:4422-4431.
    PubMed     Abstract available
    
    
    
95. SOLOMON P, Kaurani L, Budde M, Guine JB, et al
    Integrative analysis of miRNA expression profiles reveals distinct and common molecular mechanisms underlying broad diagnostic groups of severe mental disorders.
    Mol Psychiatry. 2025;30:4364-4383.
    PubMed     Abstract available
    
    
    
96. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
    Exploring the implications of case selection methods for psychiatric molecular genetic studies.
    Mol Psychiatry. 2025;30:4334-4342.
    PubMed     Abstract available
    
    
    
97. STEIN F, Gudjons AM, Brosch K, Keunecke LM, et al
    Transdiagnostic types of formal thought disorder and their association with gray matter brain structure: a model-based cluster analytic approach.
    Mol Psychiatry. 2025;30:4286-4295.
    PubMed     Abstract available
    
    
    
98. HOLTER KM, Klausner MG, Hite MH, Moriarty CT, et al
    17beta-estradiol status alters NMDAR function and antipsychotic-like activity in female rats.
    Mol Psychiatry. 2025;30:4161-4175.
    PubMed     Abstract available
    
    
    August 2025
99. WOODS RM, Potter HG, Kowash HM, McEwan F, et al
    Developmental modulation of schizophrenia risk gene methylation in offspring exhibiting cognitive deficits following maternal immune activation.
    Mol Psychiatry. 2025 Aug 29. doi: 10.1038/s41380-025-03147.
    PubMed     Abstract available
    
    
    
100. FAN YS, Xu Y, Hettwer MD, Yang P, et al
     Neurodevelopmentally rooted epicenters in schizophrenia: sensorimotor-association spatial axis of cortical thickness alterations.
     Mol Psychiatry. 2025 Aug 28. doi: 10.1038/s41380-025-03193.
     PubMed     Abstract available
     
     
     
101. UNZUETA-LARRINAGA P, Cuesta-Vega E, Barrena-Barbadillo R, Olabarrieta E, et al
     Extracellular matrix dysfunction and synaptic alterations in schizophrenia.
     Mol Psychiatry. 2025 Aug 27. doi: 10.1038/s41380-025-03154.
     PubMed     Abstract available
     
     
     
102. CUI Y, Sun J, Zhang B, Guo T, et al
     Efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with treatment-resistant schizophrenia with predominantly negative symptoms: a randomized clinical trial and efficacy sensitivity biomarkers.
     Mol Psychiatry. 2025 Aug 26. doi: 10.1038/s41380-025-03132.
     PubMed     Abstract available
     
     
     
103. WAKUDA T, Yokokura M, Magata Y, Suzuki C, et al
     alpha7 nicotinic acetylcholine receptor, activated glia, and cognitive impairment in schizophrenia: a dual-tracer PET study.
     Mol Psychiatry. 2025 Aug 19. doi: 10.1038/s41380-025-03162.
     PubMed     Abstract available
     
     
     
104. VAZIRI N, Shutt TE, Karim W, Raedler TJ, et al
     Examination of mitochondria- and inflammasome-mediated mechanisms of clozapine-induced myocarditis using patient-derived iPSC cardiomyocytes.
     Mol Psychiatry. 2025;30:3491-3501.
     PubMed     Abstract available
     
     
     July 2025
105. SALAMONE PC, Enmalm A, Kaldewaij R, Aman M, et al
     Altered processing of self-produced sensations in psychosis at cortical and spinal levels.
     Mol Psychiatry. 2025 Jul 25. doi: 10.1038/s41380-025-03130.
     PubMed     Abstract available
     
     
     
106. GARCIA-RIZO C, Bitanihirwe BKY
     Epiphenomena in psychosis: how perinatal stressful events shape long-term outcomes.
     Mol Psychiatry. 2025 Jul 11. doi: 10.1038/s41380-025-03096.
     PubMed     Abstract available
     
     
     
107. LI H, Zhao Z, Jiang S, Wu H, et al
     Brain circuits that regulate social behavior.
     Mol Psychiatry. 2025;30:3240-3256.
     PubMed     Abstract available
     
     
     
108. HAGENBEEK FA, Pool R, Van Asselt AJ, Ehli EA, et al
     Intergenerational transmission of complex traits and the offspring methylome.
     Mol Psychiatry. 2025;30:3338-3347.
     PubMed     Abstract available
     
     
     
109. HERRERO F, Heeb C, Meier M, Lin HY, et al
     Recapitulation and reversal of neuropsychiatric phenotypes in a mouse model of human endogenous retrovirus type W expression.
     Mol Psychiatry. 2025;30:3325-3337.
     PubMed     Abstract available
     
     
     
110. KIM H, Jung JH, Han K, Jeon HJ, et al
     Risk of suicide and all-cause death in patients with mental disorders: a nationwide cohort study.
     Mol Psychiatry. 2025;30:2831-2839.
     PubMed     Abstract available
     
     
     
111. LUYKX JJ, Corbeil O, Karkkainen O, Tanskanen A, et al
     Long term safety of ADHD medication in patients with schizophrenia spectrum disorders.
     Mol Psychiatry. 2025 Jul 1. doi: 10.1038/s41380-025-03080.
     PubMed     Abstract available
     
     
     June 2025
112. SZESZKO PR, Kowalchyk M, Chu KW, Aladin S, et al
     Investigation of brain white matter and social cognition in schizophrenia and schizotypal personality disorder using neurite orientation dispersion and density imaging.
     Mol Psychiatry. 2025 Jun 7. doi: 10.1038/s41380-025-03074.
     PubMed     Abstract available
     
     
     
113. SUI YV, Bertisch H, Goff DC, Samsonov A, et al
     Quantitative magnetization transfer and g-ratio imaging of white matter myelin in early psychotic spectrum disorders.
     Mol Psychiatry. 2025;30:2739-2747.
     PubMed     Abstract available
     
     
     May 2025
114. VILLARIN JM, Kellendonk C
     An ace in the hole? Opportunities and limits of using mice to understand schizophrenia neurobiology.
     Mol Psychiatry. 2025 May 22. doi: 10.1038/s41380-025-03060.
     PubMed     Abstract available
     
     
     
115. BYUN AJS, Lane E, Langholm C, Flathers M, et al
     Towards clinical subtypes in schizophrenia: integrating cognitive, functional, and digital phenotyping assessments.
     Mol Psychiatry. 2025 May 20. doi: 10.1038/s41380-025-03054.
     PubMed     Abstract available
     
     
     
116. SAINT-GEORGES Z, MacDonald J, Al-Khalili R, Hamati R, et al
     Cholinergic system in schizophrenia: A systematic review and meta-analysis.
     Mol Psychiatry. 2025 May 20. doi: 10.1038/s41380-025-03023.
     PubMed     Abstract available
     
     
     
117. HUA L, Zeng X, Zhang K, Zhao Z, et al
     Reduced glymphatic clearance in early psychosis.
     Mol Psychiatry. 2025 May 19. doi: 10.1038/s41380-025-03058.
     PubMed     Abstract available
     
     
     
118. BANERJEE A, Wang HY, Borgmann-Winter KE, MacDonald ML, et al
     Editorial Expression of Concern: Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia.
     Mol Psychiatry. 2025 May 13. doi: 10.1038/s41380-025-03050.
     PubMed    
     
     
     
119. FARHANGDOOST N, Liao C, Liu Y, Rochefort D, et al
     Transcriptomic and epigenomic consequences of heterozygous loss-of-function mutations in AKAP11, a shared risk gene for bipolar disorder and schizophrenia.
     Mol Psychiatry. 2025 May 2. doi: 10.1038/s41380-025-03040.
     PubMed     Abstract available
     
     
     
120. HATANO M, Nakajima W, Tani H, Uchida H, et al
     Characterization of patients with major psychiatric disorders with AMPA receptor positron emission tomography.
     Mol Psychiatry. 2025;30:1780-1790.
     PubMed     Abstract available
     
     
     April 2025
121. WANG HY, MacDonald ML, Borgmann-Winter KE, Banerjee A, et al
     Retraction Note: mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia.
     Mol Psychiatry. 2025 Apr 17. doi: 10.1038/s41380-025-02986.
     PubMed    
     
     
     
122. HATZIPANAYIOTI A, Walther S, Gangl N, Conring F, et al
     Aberrant personal space is associated with paranoia, altered stress regulation, and unfavourable outcomes at 6 months' follow-up in schizophrenia.
     Mol Psychiatry. 2025 Apr 9. doi: 10.1038/s41380-025-02999.
     PubMed     Abstract available
     
     
     
123. NUCIFORA LG, Ishizuka K, El Demerdash N, Lee BJ, et al
     Protein aggregation identified in olfactory neuronal cells is associated with cognitive impairments in a subset of living schizophrenia patients.
     Mol Psychiatry. 2025 Apr 3. doi: 10.1038/s41380-025-02956.
     PubMed     Abstract available
     
     
     
124. XIE Y, Fu J, Liu L, Wang X, et al
     Genetic and neural mechanisms shared by schizophrenia and depression.
     Mol Psychiatry. 2025 Apr 3. doi: 10.1038/s41380-025-02975.
     PubMed     Abstract available
     
     
     
125. YAO S, Kendrick KM
     How does oxytocin modulate human behavior?
     Mol Psychiatry. 2025;30:1639-1651.
     PubMed     Abstract available
     
     
     
126. MIURA K, Yoshida M, Morita K, Fujimoto M, et al
     Gaze behaviors during free viewing revealed differences in visual salience processing across four major psychiatric disorders: a mega-analysis study of 1012 individuals.
     Mol Psychiatry. 2025;30:1594-1600.
     PubMed     Abstract available
     
     
     
127. ITAHASHI T, Yamashita A, Takahara Y, Yahata N, et al
     Generalizable and transportable resting-state neural signatures characterized by functional networks, neurotransmitters, and clinical symptoms in autism.
     Mol Psychiatry. 2025;30:1466-1478.
     PubMed     Abstract available
     
     
     March 2025
128. GIACOMEL A, Martins D, Nordio G, Easmin R, et al
     Correction: Investigating dopaminergic abnormalities in schizophrenia and first-episode psychosis with normative modelling and multisite molecular neuroimaging.
     Mol Psychiatry. 2025 Mar 31. doi: 10.1038/s41380-025-02987.
     PubMed    
     
     
     
129. RABALLO A, Poletti M, Preti A
     Increasing conceptual clarity and confounders identification: a pragmatic way to enhance prognostic precision in ENIGMA clinical high risk for psychosis (CHR-P).
     Mol Psychiatry. 2025 Mar 17. doi: 10.1038/s41380-025-02948.
     PubMed    
     
     
     
130. FENG YA, Chen WJ, Lin MC, Hsu JS, et al
     Paternal age, de novo mutation, and age at onset among co-affected schizophrenia sib-pairs: whole-genome sequencing in multiplex families.
     Mol Psychiatry. 2025 Mar 5. doi: 10.1038/s41380-025-02942.
     PubMed     Abstract available
     
     
     
131. ZHAO Q, Wei X, Yu W, Li X, et al
     Morphological alterations of the thymus gland in individuals with schizophrenia.
     Mol Psychiatry. 2025 Mar 4. doi: 10.1038/s41380-025-02946.
     PubMed     Abstract available
     
     
     
132. ARBABI K, Newton DF, Oh H, Davie MC, et al
     Transcriptomic pathology of neocortical microcircuit cell types across psychiatric disorders.
     Mol Psychiatry. 2025;30:1057-1068.
     PubMed     Abstract available
     
     
     
133. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
     The number of episodes of major psychiatric and substance use disorders as an index of genetic risk and genetic heterogeneity.
     Mol Psychiatry. 2025;30:968-975.
     PubMed     Abstract available
     
     
     February 2025
134. GIACOMEL A, Martins D, Nordio G, Easmin R, et al
     Investigating dopaminergic abnormalities in schizophrenia and first-episode psychosis with normative modelling and multisite molecular neuroimaging.
     Mol Psychiatry. 2025 Feb 28. doi: 10.1038/s41380-025-02938.
     PubMed     Abstract available
     
     
     
135. KEIHANI A, Donati FL, Janssen SA, Huston CA, et al
     Multimodal evidence of mediodorsal thalamus-prefrontal circuit dysfunctions in clinical high-risk for psychosis: findings from a combined 7T fMRI, MRSI and sleep Hd-EEG study.
     Mol Psychiatry. 2025 Feb 15. doi: 10.1038/s41380-025-02924.
     PubMed     Abstract available
     
     
     
136. MINICHINO A, Davies C, Karpenko O, Christodoulou N, et al
     Preventing psychosis in people at clinical high risk: an updated meta-analysis by the World Psychiatric Association Preventive Psychiatry section.
     Mol Psychiatry. 2025 Feb 14. doi: 10.1038/s41380-025-02902.
     PubMed     Abstract available
     
     
     
137. DI RE J, Marini M, Hussain SI, Singh AK, et al
     betaIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia.
     Mol Psychiatry. 2025 Feb 7. doi: 10.1038/s41380-025-02917.
     PubMed     Abstract available
     
     
     
138. VINKE LN, Avanaki M, Jeffrey C, Harikumar A, et al
     Neural correlates of personal space regulation in psychosis: role of the inferior parietal cortex.
     Mol Psychiatry. 2025 Feb 3. doi: 10.1038/s41380-025-02906.
     PubMed     Abstract available
     
     
     January 2025
139. CHESTNYKH D, Muhle C, Schumacher F, Kalinichenko LS, et al
     Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia.
     Mol Psychiatry. 2025 Jan 17. doi: 10.1038/s41380-025-02893.
     PubMed     Abstract available
     
     
     
140. MARQUES D, Vaziri N, Greenway SC, Bousman C, et al
     DNA methylation and histone modifications associated with antipsychotic treatment: a systematic review.
     Mol Psychiatry. 2025;30:296-309.
     PubMed     Abstract available
     
     
     
141. CIULKINYTE A, Mountford HS, Fontanillas P, Bates TC, et al
     Genetic neurodevelopmental clustering and dyslexia.
     Mol Psychiatry. 2025;30:140-150.
     PubMed     Abstract available
     
     
     
142. LI X, Xue C, Zhu Z, Yu X, et al
     Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis.
     Mol Psychiatry. 2025;30:111-121.
     PubMed     Abstract available
     
     
     December 2024
143. EISENBERG DP, Blackman RK, Tietcheu MG, Kohn PD, et al
     Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D(2/3) receptor availability in healthy individuals.
     Mol Psychiatry. 2024 Dec 27. doi: 10.1038/s41380-024-02873.
     PubMed     Abstract available
     
     
     
144. XIA C, Alliey-Rodriguez N, Tamminga CA, Keshavan MS, et al
     Genetic analysis of psychosis Biotypes: shared Ancestry-adjusted polygenic risk and unique genomic associations.
     Mol Psychiatry. 2024 Dec 21. doi: 10.1038/s41380-024-02876.
     PubMed     Abstract available
     
     
     
145. SOLMI M, Fornaro M, Caiolo S, Lussignoli M, et al
     Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis.
     Mol Psychiatry. 2024 Dec 18. doi: 10.1038/s41380-024-02733.
     PubMed     Abstract available
     
     
     
146. COHEN LS, Arakelian M, Church TR, Dunk MM, et al
     The phenomenology of postpartum psychosis: preliminary findings from the Massachusetts General Hospital Postpartum Psychosis Project.
     Mol Psychiatry. 2024 Dec 6. doi: 10.1038/s41380-024-02856.
     PubMed     Abstract available
     
     
     
147. BERNSTEIN HG, Nussbaumer M, Vasilevska V, Dobrowolny H, et al
     Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration.
     Mol Psychiatry. 2024 Dec 5. doi: 10.1038/s41380-024-02861.
     PubMed     Abstract available
     
     
     
148. SCHALBROECK R, van Hooijdonk CFM, Bos DPA, Booij J, et al
     Chronic social stressors and striatal dopamine functioning in humans: A systematic review of SPECT and PET studies.
     Mol Psychiatry. 2024;29:3841-3856.
     PubMed     Abstract available
     
     
     November 2024
149. SABE M, Sulstarova A, Glangetas A, De Pieri M, et al
     Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
     Mol Psychiatry. 2024 Nov 27. doi: 10.1038/s41380-024-02800.
     PubMed     Abstract available
     
     
     
150. NELSON EA, Kraguljac NV, Bashir A, Cofield SS, et al
     A longitudinal study of hippocampal subfield volumes and hippocampal glutamate levels in antipsychotic-naive first episode psychosis patients.
     Mol Psychiatry. 2024 Nov 23. doi: 10.1038/s41380-024-02812.
     PubMed     Abstract available
     
     
     
151. WEIDENAUER A, Dajic I, Praschak-Rieder N, Willeit M, et al
     The dopaminergic basis of negative symptoms in schizophrenia: an addendum.
     Mol Psychiatry. 2024 Nov 20. doi: 10.1038/s41380-024-02828.
     PubMed    
     
     
     
152. CHEN L, Huai C, Song C, Wu S, et al
     Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction.
     Mol Psychiatry. 2024 Nov 19. doi: 10.1038/s41380-024-02841.
     PubMed     Abstract available
     
     
     
153. WALKER A, Karlsson R, Szatkiewicz JP, Thornton LM, et al
     Genome-wide copy number variation association study in anorexia nervosa.
     Mol Psychiatry. 2024 Nov 12. doi: 10.1038/s41380-024-02811.
     PubMed     Abstract available
     
     
     
154. NISHA AJI K, Lalang N, Ramos-Jimenez C, Rahimian R, et al
     Evidence of altered monoamine oxidase B, an astroglia marker, in early psychosis and high-risk state.
     Mol Psychiatry. 2024 Nov 7. doi: 10.1038/s41380-024-02816.
     PubMed     Abstract available
     
     
     
155. SOCRATES AJ, Mullins N, Gur RC, Gur RE, et al
     Polygenic risk of social isolation behavior and its influence on psychopathology and personality.
     Mol Psychiatry. 2024;29:3599-3606.
     PubMed     Abstract available
     
     
     
156. LUO J, Li L, Niu M, Kong D, et al
     Genetic regulation of human brain proteome reveals proteins implicated in psychiatric disorders.
     Mol Psychiatry. 2024;29:3330-3343.
     PubMed     Abstract available
     
     
     October 2024
157. LEE H, Lee JH, Lee S, Lim JS, et al
     Comorbid health outcomes in patients with schizophrenia: an umbrella review of systematic reviews and meta-analyses.
     Mol Psychiatry. 2024 Oct 18. doi: 10.1038/s41380-024-02792.
     PubMed     Abstract available
     
     
     
158. DEVINE EA, Imami AS, Eby H, Sahay S, et al
     Neuronal alterations in AKT isotype expression in schizophrenia.
     Mol Psychiatry. 2024 Oct 18. doi: 10.1038/s41380-024-02770.
     PubMed     Abstract available
     
     
     
159. SCOTT DS, Subramanian M, Yamamoto J, Tamminga CA, et al
     Schizophrenia pathology reverse-translated into mouse shows hippocampal hyperactivity, psychosis behaviors and hyper-synchronous events.
     Mol Psychiatry. 2024 Oct 16. doi: 10.1038/s41380-024-02781.
     PubMed     Abstract available
     
     
     
160. DEMPSTER EL, Wong CCY, Burrage J, Hannon E, et al
     Methylomic signature of current cannabis use in two first-episode psychosis cohorts.
     Mol Psychiatry. 2024 Oct 16. doi: 10.1038/s41380-024-02689.
     PubMed     Abstract available
     
     
     
161. KEANE BP, Abrham YT, Cole MW, Johnson BA, et al
     Functional dysconnectivity of visual and somatomotor networks yields a simple and robust biomarker for psychosis.
     Mol Psychiatry. 2024 Oct 4. doi: 10.1038/s41380-024-02767.
     PubMed     Abstract available
     
     
     
162. LIUFU C, Luo L, Pang T, Zheng H, et al
     Integration of multi-omics summary data reveals the role of N6-methyladenosine in neuropsychiatric disorders.
     Mol Psychiatry. 2024;29:3141-3150.
     PubMed     Abstract available
     
     
     September 2024
163. CHOE E, Kim M, Choi S, Oh H, et al
     MRI textural plasticity in limbic gray matter associated with clinical response to electroconvulsive therapy for psychosis.
     Mol Psychiatry. 2024 Sep 26. doi: 10.1038/s41380-024-02755.
     PubMed     Abstract available
     
     
     
164. SAPIENZA J, Martini F, Comai S, Cavallaro R, et al
     Psychedelics and schizophrenia: a double-edged sword.
     Mol Psychiatry. 2024 Sep 18. doi: 10.1038/s41380-024-02743.
     PubMed     Abstract available
     
     
     
165. KILTSCHEWSKIJ DJ, Reay WR, Cairns MJ
     Schizophrenia is associated with altered DNA methylation variance.
     Mol Psychiatry. 2024 Sep 13. doi: 10.1038/s41380-024-02749.
     PubMed     Abstract available
     
     
     
166. GARCIA-SAN-MARTIN N, Bethlehem RAI, Mihalik A, Seidlitz J, et al
     Molecular and micro-architectural mapping of gray matter alterations in psychosis.
     Mol Psychiatry. 2024 Sep 12. doi: 10.1038/s41380-024-02724.
     PubMed     Abstract available
     
     
     
167. NANI JV, Muotri AR, Hayashi MAF
     Peering into the mind: unraveling schizophrenia's secrets using models.
     Mol Psychiatry. 2024 Sep 8. doi: 10.1038/s41380-024-02728.
     PubMed     Abstract available
     
     
     
168. ROMANOVSKY E, Choudhary A, Peles D, Abu-Akel A, et al
     Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients' neurons.
     Mol Psychiatry. 2024 Sep 5. doi: 10.1038/s41380-024-02740.
     PubMed     Abstract available
     
     
     
169. PHADKE RA, Brack A, Fournier LA, Kruzich E, et al
     The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking.
     Mol Psychiatry. 2024 Sep 3. doi: 10.1038/s41380-024-02701.
     PubMed     Abstract available
     
     
     
170. CHAN JKN, Lee KCK, Correll CU, So YK, et al
     Adverse obstetric and neonatal outcomes associated with maternal schizophrenia-spectrum disorders and prenatal antipsychotic use: a meta-analysis of 37,214,330 pregnancy deliveries and propensity-score weighted population-based cohort study assessing
     Mol Psychiatry. 2024 Sep 2. doi: 10.1038/s41380-024-02723.
     PubMed     Abstract available
     
     
     
171. CROUSE JJ, Park SH, Byrne EM, Mitchell BL, et al
     Patterns of stressful life events and polygenic scores for five mental disorders and neuroticism among adults with depression.
     Mol Psychiatry. 2024;29:2765-2773.
     PubMed     Abstract available
     
     
     
172. GAITONDE SA, Avet C, de la Fuente Revenga M, Blondel-Tepaz E, et al
     Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT(2A) receptor.
     Mol Psychiatry. 2024;29:2753-2764.
     PubMed     Abstract available
     
     
     
173. KAMPE A, Suvisaari J, Lahteenvuo M, Singh T, et al
     Genetic contribution to disease-course severity and progression in the SUPER-Finland study, a cohort of 10,403 individuals with psychotic disorders.
     Mol Psychiatry. 2024;29:2733-2741.
     PubMed     Abstract available
     
     
     
174. GERACI F, Passiatore R, Penzel N, Laudani S, et al
     Sex dimorphism controls dysbindin-related cognitive dysfunctions in mice and humans with the contribution of COMT.
     Mol Psychiatry. 2024;29:2666-2677.
     PubMed     Abstract available
     
     
     August 2024
175. KAMBALI M, Li Y, Unichenko P, Feria Pliego JA, et al
     An increased copy number of glycine decarboxylase (GLDC) associated with psychosis reduces extracellular glycine and impairs NMDA receptor function.
     Mol Psychiatry. 2024 Aug 30. doi: 10.1038/s41380-024-02711.
     PubMed     Abstract available
     
     
     
176. AYMERICH C, Salazar de Pablo G, Pacho M, Perez-Rodriguez V, et al
     All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis.
     Mol Psychiatry. 2024 Aug 22. doi: 10.1038/s41380-024-02694.
     PubMed     Abstract available
     
     
     
177. LI Z, Mukherjee D, Duric B, Austin-Zimmerman I, et al
     Systematic review and meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on schizophrenia-like behaviour in rodents.
     Mol Psychiatry. 2024 Aug 2. doi: 10.1038/s41380-024-02668.
     PubMed     Abstract available
     
     
     
178. ALLOTT K, Chopra S, Rogers J, Dauvermann MR, et al
     Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action.
     Mol Psychiatry. 2024;29:2571-2574.
     PubMed    
     
     
     July 2024
179. FORNARO M, Caiazza C, Billeci M, Berk M, et al
     Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ".
     Mol Psychiatry. 2024 Jul 18. doi: 10.1038/s41380-024-02645.
     PubMed     Abstract available
     
     
     
180. ARANDA S, Jimenez E, Canales-Rodriguez EJ, Verdolini N, et al
     Processing speed mediates the relationship between DDR1 and psychosocial functioning in euthymic patients with bipolar disorder presenting psychotic symptoms.
     Mol Psychiatry. 2024;29:2050-2058.
     PubMed     Abstract available
     
     
     June 2024
181. CAMPORESI S, Xin L, Golay P, Eap CB, et al
     Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study.
     Mol Psychiatry. 2024 Jun 7. doi: 10.1038/s41380-024-02631.
     PubMed     Abstract available
     
     
     
182. MARTINO M, Magioncalda P
     A working model of neural activity and phenomenal experience in psychosis.
     Mol Psychiatry. 2024 Jun 6. doi: 10.1038/s41380-024-02607.
     PubMed     Abstract available
     
     
     
183. CHO KIK, Zhang F, Penzel N, Seitz-Holland J, et al
     Excessive interstitial free-water in cortical gray matter preceding accelerated volume changes in individuals at clinical high risk for psychosis.
     Mol Psychiatry. 2024 Jun 3. doi: 10.1038/s41380-024-02597.
     PubMed     Abstract available
     
     
     
184. LIAO Y, Yu H, Zhang Y, Lu Z, et al
     Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation.
     Mol Psychiatry. 2024;29:1857-1868.
     PubMed     Abstract available
     
     
     May 2024
185. STERN S, Zhang L, Wang M, Wright R, et al
     Monozygotic twins discordant for schizophrenia differ in maturation and synaptic transmission.
     Mol Psychiatry. 2024 May 4. doi: 10.1038/s41380-024-02561.
     PubMed     Abstract available
     
     
     
186. HILL MD, Gill SS, Le-Niculescu H, MacKie O, et al
     Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics.
     Mol Psychiatry. 2024;29:1528-1549.
     PubMed     Abstract available
     
     
     
187. YANG K, Hasegawa Y, Bhattarai JP, Hua J, et al
     Inflammation-related pathology in the olfactory epithelium: its impact on the olfactory system in psychotic disorders.
     Mol Psychiatry. 2024;29:1453-1464.
     PubMed     Abstract available
     
     
     April 2024
188. SPATHOPOULOU A, Sauerwein GA, Marteau V, Podlesnic M, et al
     Integrative metabolomics-genomics analysis identifies key networks in a stem cell-based model of schizophrenia.
     Mol Psychiatry. 2024 Apr 29. doi: 10.1038/s41380-024-02568.
     PubMed     Abstract available
     
     
     
189. SHARKEY RJ, Bacon C, Peterson Z, Rootes-Murdy K, et al
     Differences in the neural correlates of schizophrenia with positive and negative formal thought disorder in patients with schizophrenia in the ENIGMA dataset.
     Mol Psychiatry. 2024 Apr 26. doi: 10.1038/s41380-024-02563.
     PubMed     Abstract available
     
     
     
190. SUPEKAR K, de Los Angeles C, Ryali S, Kushan L, et al
     Robust and replicable functional brain signatures of 22q11.2 deletion syndrome and associated psychosis: a deep neural network-based multi-cohort study.
     Mol Psychiatry. 2024 Apr 12. doi: 10.1038/s41380-024-02495.
     PubMed     Abstract available
     
     
     
191. TOTZEK JF, Chakravarty MM, Joober R, Malla A, et al
     Longitudinal inference of multiscale markers in psychosis: from hippocampal centrality to functional outcome.
     Mol Psychiatry. 2024 Apr 11. doi: 10.1038/s41380-024-02549.
     PubMed     Abstract available
     
     
     
192. OKADA N, Yahata N, Koshiyama D, Morita K, et al
     Longitudinal trajectories of anterior cingulate glutamate and subclinical psychotic experiences in early adolescence: the impact of bullying victimization.
     Mol Psychiatry. 2024;29:939-950.
     PubMed     Abstract available
     
     
     March 2024
193. CHEN S, Tan Y, Tian L
     Immunophenotypes in psychosis: is it a premature inflamm-aging disorder?
     Mol Psychiatry. 2024 Mar 26. doi: 10.1038/s41380-024-02539.
     PubMed     Abstract available
     
     
     
194. KOSKUVI M, Porsti E, Hewitt T, Rasanen N, et al
     Genetic contribution to microglial activation in schizophrenia.
     Mol Psychiatry. 2024 Mar 22. doi: 10.1038/s41380-024-02529.
     PubMed     Abstract available
     
     
     
195. TESFAYE M, Spindola LM, Stavrum AK, Shadrin A, et al
     Sex effects on DNA methylation affect discovery in epigenome-wide association study of schizophrenia.
     Mol Psychiatry. 2024 Mar 19. doi: 10.1038/s41380-024-02513.
     PubMed     Abstract available
     
     
     
196. FEOLA B, Beermann A, Manzanarez Felix K, Coleman M, et al
     Data-driven, connectome-wide analysis identifies psychosis-specific brain correlates of fear and anxiety.
     Mol Psychiatry. 2024 Mar 19. doi: 10.1038/s41380-024-02512.
     PubMed     Abstract available
     
     
     
197. BIGDELI TB, Barr PB, Rajeevan N, Graham DP, et al
     Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder.
     Mol Psychiatry. 2024 Mar 15. doi: 10.1038/s41380-024-02472.
     PubMed     Abstract available
     
     
     
198. WARREN TL, Tubbs JD, Lesh TA, Corona MB, et al
     Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis.
     Mol Psychiatry. 2024 Mar 15. doi: 10.1038/s41380-024-02457.
     PubMed     Abstract available
     
     
     February 2024
199. FOUNTOULAKIS KN, Tsapakis EM
     Neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders.
     Mol Psychiatry. 2024 Feb 19. doi: 10.1038/s41380-024-02458.
     PubMed    
     
     
     
200. SONG J, Jonsson L, Lu Y, Bergen SE, et al
     Key subphenotypes of bipolar disorder are differentially associated with polygenic liabilities for bipolar disorder, schizophrenia, and major depressive disorder.
     Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02448.
     PubMed     Abstract available
     
     
     
201. BENRIMOH D, Dlugunovych V, Wright AC, Phalen P, et al
     Correction: On the proportion of patients who experience a prodrome prior to psychosis onset: a systematic review and meta-analysis.
     Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02481.
     PubMed    
     
     
     
202. KOTOV R, Carpenter WT, Cicero DC, Correll CU, et al
     Psychosis superspectrum II: neurobiology, treatment, and implications.
     Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02410.
     PubMed     Abstract available
     
     
     
203. ZHU Y, Maikusa N, Radua J, Samann PG, et al
     Using brain structural neuroimaging measures to predict psychosis onset for individuals at clinical high-risk.
     Mol Psychiatry. 2024 Feb 9. doi: 10.1038/s41380-024-02426.
     PubMed     Abstract available
     
     
     
204. GEORGIADIS F, Lariviere S, Glahn D, Hong LE, et al
     Connectome architecture shapes large-scale cortical alterations in schizophrenia: a worldwide ENIGMA study.
     Mol Psychiatry. 2024 Feb 9. doi: 10.1038/s41380-024-02442.
     PubMed     Abstract available
     
     
     
205. BENRIMOH D, Dlugunovych V, Wright AC, Phalen P, et al
     On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis.
     Mol Psychiatry. 2024 Feb 2. doi: 10.1038/s41380-024-02415.
     PubMed     Abstract available
     
     
     
206. PODVIN S, Jones J, Kang A, Goodman R, et al
     Human iN neuronal model of schizophrenia displays dysregulation of chromogranin B and related neuropeptide transmitter signatures.
     Mol Psychiatry. 2024 Feb 2. doi: 10.1038/s41380-024-02422.
     PubMed     Abstract available
     
     
     
207. SHAKESHAFT A, Martin J, Dennison CA, Riglin L, et al
     Estimating the impact of transmitted and non-transmitted psychiatric and neurodevelopmental polygenic scores on youth emotional problems.
     Mol Psychiatry. 2024;29:238-246.
     PubMed     Abstract available
     
     
     January 2024
208. CHUNG Y, Dienel SJ, Belch MJ, Fish KN, et al
     Altered Rbfox1-Vamp1 pathway and prefrontal cortical dysfunction in schizophrenia.
     Mol Psychiatry. 2024 Jan 25. doi: 10.1038/s41380-024-02417.
     PubMed     Abstract available
     
     
     
209. CHEN H, Lei Y, Li R, Xia X, et al
     Resting-state EEG dynamic functional connectivity distinguishes non-psychotic major depression, psychotic major depression and schizophrenia.
     Mol Psychiatry. 2024 Jan 24. doi: 10.1038/s41380-023-02395.
     PubMed     Abstract available
     
     
     
210. DAVIES C, Martins D, Dipasquale O, McCutcheon RA, et al
     Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin.
     Mol Psychiatry. 2024 Jan 19. doi: 10.1038/s41380-024-02406.
     PubMed     Abstract available
     
     
     
211. WOLFF A, Northoff G
     Temporal imprecision of phase coherence in schizophrenia and psychosis-dynamic mechanisms and diagnostic marker.
     Mol Psychiatry. 2024 Jan 16. doi: 10.1038/s41380-023-02337.
     PubMed     Abstract available
     
     
     
212. JONAS KG, Cannon TD, Docherty AR, Dwyer D, et al
     Psychosis superspectrum I: Nosology, etiology, and lifespan development.
     Mol Psychiatry. 2024 Jan 10. doi: 10.1038/s41380-023-02388.
     PubMed     Abstract available
     
     
     
213. SI S, Bi A, Yu Z, See C, et al
     Mapping gray and white matter volume abnormalities in early-onset psychosis: an ENIGMA multicenter voxel-based morphometry study.
     Mol Psychiatry. 2024 Jan 10. doi: 10.1038/s41380-023-02343.
     PubMed     Abstract available
     
     
     
214. RUBIO JM, Lencz T, Cao H, Kraguljac N, et al
     Replication of a neuroimaging biomarker for striatal dysfunction in psychosis.
     Mol Psychiatry. 2024 Jan 4. doi: 10.1038/s41380-023-02381.
     PubMed     Abstract available
     
     
     December 2023
215. DONG P, Voloudakis G, Fullard JF, Hoffman GE, et al
     Convergence of the dysregulated regulome in schizophrenia with polygenic risk and evolutionarily constrained enhancers.
     Mol Psychiatry. 2023 Dec 25. doi: 10.1038/s41380-023-02370.
     PubMed     Abstract available
     
     
     
216. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
     The relationship between familial-genetic risk and pharmacological treatment in a Swedish national sample of patients with major depression, bipolar disorder, and schizophrenia.
     Mol Psychiatry. 2023 Dec 20. doi: 10.1038/s41380-023-02365.
     PubMed     Abstract available
     
     
     
217. KOMATSU H, Onoguchi G, Silverstein SM, Jerotic S, et al
     Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography.
     Mol Psychiatry. 2023 Dec 11. doi: 10.1038/s41380-023-02340.
     PubMed     Abstract available
     
     
     
218. OKADA N, Fukunaga M, Miura K, Nemoto K, et al
     Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification.
     Mol Psychiatry. 2023;28:5206-5216.
     PubMed     Abstract available
     
     
     
219. GRIECO SF, Johnston KG, Gao P, Garduno BM, et al
     Anatomical and molecular characterization of parvalbumin-cholecystokinin co-expressing inhibitory interneurons: implications for neuropsychiatric conditions.
     Mol Psychiatry. 2023;28:5293-5308.
     PubMed     Abstract available
     
     
     
220. WEI W, Deng L, Qiao C, Yin Y, et al
     Neural variability in three major psychiatric disorders.
     Mol Psychiatry. 2023;28:5217-5227.
     PubMed     Abstract available
     
     
     
221. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
     Selecting cases of major psychiatric and substance use disorders in Swedish national registries on the basis of clinical features to maximize the strength or specificity of the genetic risk.
     Mol Psychiatry. 2023;28:5195-5205.
     PubMed     Abstract available
     
     
     
222. ZHENG H, Webster MJ, Weickert CS, Beasley CL, et al
     Cytomegalovirus antibodies are associated with mood disorders, suicide, markers of neuroinflammation, and microglia activation in postmortem brain samples.
     Mol Psychiatry. 2023;28:5282-5292.
     PubMed     Abstract available
     
     
     November 2023
223. NORTHOFF G, Daub J, Hirjak D
     Overcoming the translational crisis of contemporary psychiatry - converging phenomenological and spatiotemporal psychopathology.
     Mol Psychiatry. 2023;28:4492-4499.
     PubMed     Abstract available
     
     
     October 2023
224. OWEN MJ, Legge SE, Rees E, Walters JTR, et al
     Genomic findings in schizophrenia and their implications.
     Mol Psychiatry. 2023 Oct 18. doi: 10.1038/s41380-023-02293.
     PubMed     Abstract available
     
     
     
225. LESH TA, Iosif AM, Tanase C, Vlasova RM, et al
     Extracellular free water elevations are associated with brain volume and maternal cytokine response in a longitudinal nonhuman primate maternal immune activation model.
     Mol Psychiatry. 2023;28:4185-4194.
     PubMed     Abstract available
     
     
     
226. ARNATKEVICIUTE A, Lemire M, Morrison C, Mooney M, et al
     Trans-ancestry meta-analysis of genome wide association studies of inhibitory control.
     Mol Psychiatry. 2023;28:4175-4184.
     PubMed     Abstract available
     
     
     
227. RAVEN EP, Veraart J, Kievit RA, Genc S, et al
     In vivo evidence of microstructural hypo-connectivity of brain white matter in 22q11.2 deletion syndrome.
     Mol Psychiatry. 2023;28:4342-4352.
     PubMed     Abstract available
     
     
     September 2023
228. ODKHUU S, Kim WS, Tsogt U, Shen J, et al
     Network biomarkers in recovered psychosis patients who discontinued antipsychotics.
     Mol Psychiatry. 2023 Sep 29. doi: 10.1038/s41380-023-02279.
     PubMed     Abstract available
     
     
     
229. HARRISON PJ, Bannerman DM
     GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia.
     Mol Psychiatry. 2023 Sep 22. doi: 10.1038/s41380-023-02265.
     PubMed     Abstract available
     
     
     
230. ZHOU J, Xia Y, Li M, Chen Y, et al
     A higher dysregulation burden of brain DNA methylation in female patients implicated in the sex bias of Schizophrenia.
     Mol Psychiatry. 2023 Sep 11. doi: 10.1038/s41380-023-02243.
     PubMed     Abstract available
     
     
     
231. FLYNN LT, Gao WJ
     DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness.
     Mol Psychiatry. 2023 Sep 7. doi: 10.1038/s41380-023-02235.
     PubMed     Abstract available
     
     
     
232. SOLMI M, Cortese S, Vita G, De Prisco M, et al
     An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders.
     Mol Psychiatry. 2023;28:3671-3687.
     PubMed     Abstract available
     
     
     
233. MERRITT K, Luque Laguna P, Sethi A, Drakesmith M, et al
     The impact of cumulative obstetric complications and childhood trauma on brain volume in young people with psychotic experiences.
     Mol Psychiatry. 2023;28:3688-3697.
     PubMed     Abstract available
     
     
     
234. WOOTTON O, Shadrin AA, Mohn C, Susser E, et al
     Genome-wide association study in 404,302 individuals identifies 7 significant loci for reaction time variability.
     Mol Psychiatry. 2023;28:4011-4019.
     PubMed     Abstract available
     
     
     
235. CAMPBELL PD, Lee I, Thyme S, Granato M, et al
     Mitochondrial proteins encoded by the 22q11.2 neurodevelopmental locus regulate neural stem and progenitor cell proliferation.
     Mol Psychiatry. 2023;28:3769-3781.
     PubMed     Abstract available
     
     
     August 2023
236. NURMI EL, Laughlin CP, de Wit H, Palmer AA, et al
     Polygenic contributions to performance on the Balloon Analogue Risk Task.
     Mol Psychiatry. 2023;28:3524-3530.
     PubMed     Abstract available
     
     
     
237. HETTEMA JM, van den Oord EJCG, Zhao M, Xie LY, et al
     Methylome-wide association study of anxiety disorders.
     Mol Psychiatry. 2023;28:3484-3492.
     PubMed     Abstract available
     
     
     May 2023
238. LICINIO J, Wong ML
     Psychosis and autism spectrum disorder: a special issue of Molecular Psychiatry.
     Mol Psychiatry. 2023;28:1830-1832.
     PubMed    
     
     
     
239. VAN DEN OORD EJCG, Xie LY, Zhao M, Campbell TL, et al
     Genes implicated by a methylome-wide schizophrenia study in neonatal blood show differential expression in adult brain samples.
     Mol Psychiatry. 2023;28:2088-2094.
     PubMed     Abstract available
     
     
     
240. MAYELI A, LaGoy AD, Smagula SF, Wilson JD, et al
     Shared and distinct abnormalities in sleep-wake patterns and their relationship with the negative symptoms of Schizophrenia Spectrum Disorder patients.
     Mol Psychiatry. 2023;28:2049-2057.
     PubMed     Abstract available
     
     
     
241. FOND G, Vidal M, Joseph M, Etchecopar-Etchart D, et al
     Self-stigma in schizophrenia: a systematic review and meta-analysis of 37 studies from 25 high- and low-to-middle income countries.
     Mol Psychiatry. 2023;28:1920-1931.
     PubMed     Abstract available
     
     
     
242. LU C, Zhu X, Feng Y, Ao W, et al
     Atypical antipsychotics antagonize GABA(A) receptors in the ventral tegmental area GABA neurons to relieve psychotic behaviors.
     Mol Psychiatry. 2023;28:2107-2121.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum